Vasopressin-stimulated Ca2+ spiking in vascular smooth muscle cells involves phospholipase D

Am J Physiol Heart Circ Physiol. 2001 Jun;280(6):H2658-64. doi: 10.1152/ajpheart.2001.280.6.H2658.

Abstract

Physiological concentrations of [Arg(8)]vasopressin (AVP; 10-500 pM) stimulate oscillations of cytosolic free Ca2+ concentration (Ca2+ spikes) in A7r5 vascular smooth muscle cells. We previously reported that this effect of AVP was blocked by a putative phospholipase A2 (PLA2) inhibitor, ONO-RS-082 (5 microM). In the present study, the products of PLA2, arachidonic acid (AA), and lysophospholipids were found to be ineffective in stimulating Ca2+ spiking, and inhibitors of AA metabolism did not prevent AVP-stimulated Ca2+ spiking. Thin layer chromatography was used to monitor the release of AA and phosphatidic acid (PA), which are the products of PLA2 and phospholipase D (PLD), respectively. AVP (100 pM) stimulated both AA and PA formation, but only PA formation was inhibited by ONO-RS-082 (5 microM). Exogenous PLD (type VII; 2.5 U/ml) stimulated Ca2+ spiking equivalent to the effect of 100 pM AVP. AVP stimulated transphosphatidylation of 1-butanol (a PLD-catalyzed reaction) but not 2-butanol, and 1-butanol (but not 2-butanol) completely prevented AVP-stimulated Ca2+ spiking. Protein kinase C (PKC) inhibition, which completely prevents AVP-stimulated Ca2+ spiking, did not inhibit AVP-stimulated phosphatidylbutanol formation. These results suggest that AVP-stimulated Ca2+ spiking depends on activation of PLD rather than PLA2 and that PKC activation may be downstream of PLD in the signaling cascade.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 1-Butanol / pharmacology
  • Aminobenzoates / pharmacology
  • Animals
  • Arachidonic Acid / metabolism
  • Arachidonic Acid / pharmacology
  • Calcium Signaling / drug effects
  • Calcium Signaling / physiology*
  • Cell Line
  • Chlorobenzoates
  • Cinnamates / pharmacology
  • Enzyme Activation / drug effects
  • Enzyme Inhibitors / pharmacology
  • Lysophospholipids / metabolism
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism*
  • Phospholipase D / metabolism*
  • Phospholipases A / antagonists & inhibitors
  • Phospholipases A / metabolism
  • Phospholipases A2
  • Protein Kinase C / antagonists & inhibitors
  • Protein Kinase C / metabolism
  • Rats
  • Tetradecanoylphorbol Acetate / pharmacology
  • Vasopressins / metabolism*
  • Vasopressins / pharmacology
  • ortho-Aminobenzoates

Substances

  • Aminobenzoates
  • Chlorobenzoates
  • Cinnamates
  • Enzyme Inhibitors
  • Lysophospholipids
  • ortho-Aminobenzoates
  • Vasopressins
  • Arachidonic Acid
  • 1-Butanol
  • 2-(4-amylcinnamoyl)amino-4-chlorobenzoic acid
  • Protein Kinase C
  • Phospholipases A
  • Phospholipases A2
  • Phospholipase D
  • Tetradecanoylphorbol Acetate